Nuvation Bio Q3 net loss widens to $55.8M; first IBTROZI revenue $7.7M

Nuvation Bio Inc.

2025-Q3 EPS reported -$0.49 revenue$21,037,000

Net loss $55.8M ($0.16 loss per share) vs. $41.2M ($0.15) in Q3 2024.
Net product revenue from IBTROZI $7.7M; collaboration revenue $5.4M (up from $0.7M).
204 new patients started IBTROZI in Q3; median duration of response matured to 50 months.
Cash, cash equivalents, and marketable securities $549.0M at Sept 30, 2025.
First patients enrolled in TRUST-IV adjuvant study and safusidenib G203 study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.